CompletedNCT00156104

Efficacy and Safety of Asenapine With Placebo and Haloperidol (41023)(P05926)(COMPLETED)

Researchers compared Asenapine, Haloperidol and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

Medication studyAges 18+

The study in practice

Understand this study

Researchers compared Asenapine, Haloperidol and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Study clarity

Study start dateStarted: July 1, 2005

Recruitment status: Completed
Enrollment listed in the registry: 460
Sponsor: Organon and Co
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug, OTHER
Study phase: Phase 3
Locations: Not clearly listed
Age range: Over 18 Years
Official registry ID: NCT00156104
Official title: Show the full official title
A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Haloperidol Positive Control in Subjects With an Acute Exacerbation of Schizophrenia

Completed

Locations not listed

FAQ

What did researchers investigate?

Researchers compared Asenapine, Haloperidol and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

Who is behind this study?

The study sponsor is Organon and Co.

Did this study involve medication?

Yes. The study involved medication, including Asenapine and Haloperidol.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.